Trials with gemtuzumab ozogamicin (Mylotarg®) combined with chemotherapy regimens in acute myeloid leukemia

Clinical Lymphoma

Volumn 2, Issue SUPPL.1, 2002, Pages

  Stadtmauer, Edward A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute myeloid leukemia; Anti CD33 antibody; Bcl 2 antisense; Cytarabine; Fludarabine; Interleukin 11; Promyelocytic leukemia

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; CALICHEAMICIN; CD33 ANTIGEN; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INTERLEUKIN 11; LIPOSOME; MITOXANTRONE; MONOCLONAL ANTIBODY; OBLIMERSEN; PROTEIN BCL 2; RETINOIC ACID; TOPOTECAN; TROXACITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MYELODYSPLASTIC SYNDROME; PROMYELOCYTIC LEUKEMIA;

EID: 0036227505     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2002.s.005     Document Type: Article

References (13)

1. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
2. Calicheamicin gamma 1I and DNA: Molecular recognition process responsible for site-specificity
3. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model
4. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
5. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
6. An updated report of the efficacy and safety of gemtuzumab ozogamicin in 188 patients with acute myeloid leukemia in first relapse
7. Gemtuzumab ozogamicin in combination with chemotherapy in AML
8. Sequential administration of gemtuzumab ozagamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC Leukemia Group trial
9. Acute myeloid leukemia
10. Gemtuzumab ozogamicin ("Mylotarg") in untreated acute promyelocytic leukemia
11. Mylotarg +/- IL-11 in patients age >= 65 with newly-diagnosed AML/MDS: Comparison with idarubicin + ara-C
12. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation